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Attentional deficits are a core symptom of schizophrenia.  Post-mortem analyses of the 
brains of schizophrenics reveal consistent abnormalities in -aminobutyric acid (GABA) 
interneurons indicative of reduced cortical GABA transmission, raising the possibility 
that this pathology contributes to attentional deficits.  We examined whether blockade of 
prefrontal cortex (PFC) GABAA receptors with bicuculline (BMI) impairs attention in rats 
using the 5-choice serial reaction time task (5CSRTT).  For comparison, we also 
examined whether administration of the GABAA receptor agonist muscimol (MUS) would 
improve attention.  In parallel we examined the effects of both manipulations on activity 
in an open field and on motivation using the intracranial self-stimulation (ICSS) test.   
BMI increased PFC neuronal activity, as reflected by increased Fos-immunolabeling, 
and impaired attention, as reflected by decreased accuracy and increased omissions.  
Although increased omissions also may reflect reductions in locomotor activity 
or motivation, the overall pattern of effects does not support either of these 
interpretations: BMI did not affect locomotor activity, and it enhanced motivation 
in the ICSS test.  MUS did not affect attention, although it increased impulsive behavior 
at a dose that suppressed PFC neuronal activity, as reflected by decreased Fos-
immunolabeling.  These impulsivity effects are not due to altered locomotor activity 
(which was decreased) or motivation (which was not affected).  Our data support the 
hypothesis that cortical GABA neurons play an important role in regulating attention and 
may have direct implications for the treatment of schizophrenia.  
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Cognitive deficits, including attentional deficits, are a core feature of 
schizophrenia (http://www.nimh.nih.gov/publicat/schizoph.cfm) and are refractory to 
currently available antipsychotic treatments.  In schizophrenia, cognitive impairments 
predate the illness onset, are stable across phases of illness, and are present in non-
schizophrenic first-degree relatives of people with schizophrenia (Cornblatt et al., 2001; 
Chen et al., 2000).  Furthermore, cognitive deficits predict patient difficulties in 
maintaining employment, living independently and having meaningful social interactions 
(Green et al., 2004).  Understanding the biological bases of these deficits may lead to 
the development of more efficacious treatments for this devastating disorder. 
Pathology in -aminobutyric acid (GABA) neurons is one of the most reliable 
abnormalities found in post-mortem analyses of the schizophrenic brain (Lewis et al., 
2005; Benes, 2010).  For example, reduced gene expression of the 67-kilodalton 
isoform of the GABA synthesizing enzyme glutamic acid decarboxylase (GAD67) and a 
corresponding reduction in gene expression of the GABA uptake transporter (GAT1) are 
observed in the prefrontal cortex (PFC) (Volk et al., 2000; Volk et al., 2001; for review, 
see Lewis et al., 2005).  These findings suggest reductions in the synthesis, release, 
and reuptake of GABA in the brains of schizophrenics.   
Within the prefrontal cortex (PFC), GABA neurons regulate the activity of efferent 
glutamatergic pyramidal neurons (Markram et al., 2004; White, 1989).  This 
microcircuitry is essential for establishing neural synchrony (i.e., gamma oscilliations) 
within cortical networks, including that evoked during attentional tasks (Bartos et al., 
2007; Gruber et al., 1999; Steinmetz et al., 2000).  Notably, people with schizophrenia 




exhibit reduced evoked gamma oscillations during cognitive tasks (Cho et al., 2006; 
Gonzalez-Burgos and Lewis, 2008).  Collectively, these findings raise the possibility that 
reduced GABA-mediated inhibition leads to reductions in neural synchrony and the 
cognitive deficits that are characteristic of schizophrenia.   
Research in laboratory animals provides support for the putative role of GABA 
neurons in the regulation of cognitive function.  For example, blockade of cortical 
GABAA receptors impairs working memory in monkeys (Sawaguchi et al., 1989) and 
attentional set-shifting in rats (Enomoto et al., 2011).  The purpose of the current 
experiment was to extend this research by determining if blockade of cortical GABAA 
receptors with bicuculline (BMI) impairs visuospatial attention in the 5-choice serial 
reaction time task (5CSRTT) in rats.  The 5CSRTT is analogous to the continuous 
performance task (CPT), which is used to quantify sustained attention in humans 
(Robbins, 2002).  Importantly, individuals with schizophrenia exhibit attentional 
deficits on the CPT (Cornblatt et al., 2001; Chen et al., 2000), providing a strong 
rationale for using the 5CSRTT to study the neurobiology of this disorder.  For 
comparison, we investigated whether low dose administration of the GABAA receptor 
agonist muscimol (MUS) could enhance attentional performance.  Because high doses 
of MUS can inhibit PFC cortical activity, we speculated that high doses of MUS would 
impair 5CSRTT performance in a manner similar to that observed following PFC lesions 
(Chudasama et al., 2003; Passetti et al., 2002; Pezze et al., 2009; Muir et al., 1996).  
We used additional tests (open field, intracranial self-stimulation [ICSS]) to determine if 
these treatments can cause changes in locomotor activity or motivation, both of which 
can affect performance in the 5CSRTT. 





Materials and Methods 
Rats 
Twenty-nine adult male Sprague-Dawley rats (Charles River Laboratories, 
Raleigh NC) were used.  Procedures began on approximately post-natal day 60.  
The rats used in the 5CSRTT and open field tests were housed in pairs whereas those 
used in the ICSS test were housed singly.  All rats were maintained on a 12-h/12-h light-
dark cycle (lights on at 0700h).  Rats were given 1 week to acclimate to the housing 
conditions with free access to food (Purina Rat Chow) and water.  Rats tested in the 
5CSRTT were food restricted to 85% of their free-feeding weights starting 24-h prior to 
the onset of training.  All rats had free access to water while in the home cage.  
Experiments were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals (National Academy Press, 1996) and McLean Hospital policies. 
 
Drugs 
(-)-Bicuculline methiodide (BMI) and muscimol (MUS) were purchased from 
Sigma-Aldrich (St. Louis MO).  Drugs were dissolved in physiological saline (0.9%).  
The dose of BMI was based upon its salt form.  
 
Surgery 
Rats were anesthetized with sodium pentobarbital (65 mg/kg, IP) and treated 
with atropine sulfate (0.25 mg/kg, SC) to minimize bronchial secretions.  Rats were 
implanted with bilateral guide cannulae (26-gauge; Plastics One, Roanoke, VA) that 




were situated at the border of infralimbic (IL) and prelimbic cortex (PrL) cortices (relative 
to bregma:  AP=+3.2, ML=±0.75, DV=-1.8 mm from dura [Paxinos and Watson, 1997]).  
Obturators and injector needles (33-gauge) extended 1.5 mm below the guide 
cannulae, into the IL/PrL.  Rats in the ICSS experiment were simultaneously implanted 
with a unilateral monopolar, stainless-steel electrode (0.25-mm diameter; Plastics One, 
Roanoke, VA) aimed at the right medial forebrain bundle at the level of the lateral 
hypothalamus (relative to bregma: AP=-2.8, ML=1.6, DV=-7.8 from dura).  The 
electrodes were coated with polyamide insulation except at the flattened tip.  Skull 
screws (one of which served as the ground) and the electrode were secured to the skull 
with dental acrylic.  
 
The 5-choice serial reaction time task (5CSRTT) 
We trained the rats as described previously (Paine et al., 2009).  Sessions 
started with the delivery of 1 food pellet (45-mg, Bio-Serv, Frenchtown NJ); the first trial 
commenced upon retrieval.  A nose poke into the magazine initiated a 5-sec inter-trial 
interval (ITI) and illumination of the house light.  At the end of the ITI, a 1.0-sec light 
stimulus was presented at the rear of one of the five stimulus locations (apertures).  
Rats had up to 5 sec (limited hold) to make a response.  A response in the illuminated 
aperture (correct response) triggered delivery of 1 food pellet and illumination of the 
magazine light, which remained illuminated for 5 sec following pellet delivery.  Nose 
pokes in the remaining apertures were considered incorrect responses and triggered a 
5-sec time-out (TO) during which the house light was extinguished.  Similarly, failure to 
respond during the limited hold (i.e., an omission) triggered a 5-sec TO.  The 




subsequent trial was initiated at the end of the TO period.  Responses occurring during 
the ITI were considered premature responses and also triggered a 5-sec TO; the same 
trial was re-started at the end of the TO period.  Responses occurring during the TO 
period had no programmed consequences.  Sessions ended after 90 trials or 30 min.  
Performance measures of interest were: % accuracy ((correct responses/ [correct + 
incorrect responses])*100), % omissions ([omissions/ trials completed]*100), premature 
responses, magazine entries, correct response latency (the time from the stimulus 
onset to a correct response) and reward latency (the time from a correct response to the 
collection of the food).  Subjects were considered to have acquired the task when their 
accuracy was greater than 60% (chance performance in this test is 20%) and omissions 
were fewer than 20% for 5 consecutive days.  Upon reaching criterion performance, the 
rats underwent surgery to implant guide cannulae. 
Rats (n=17) were allowed to recover for 7 days and then were re-stabilized for 5 
days prior to drug testing.  To habituate rats to the infusion procedure they were first 
infused with vehicle (VEH, 0.9% physiological saline); data from this session was 
discarded.  On test days, rats were infused with either BMI (0, 6.25, 12.5 or 25.0 ng/0.5 
l/side) or MUS (0, 6.25, 12.5, 25.0 or 50.0 ng/0.5 l/side) immediately prior to testing 
on the 5CSRTT.  Drug doses for half of the rats tested with each drug were 
administered in an ascending order, while the remainder of the rats received drug doses 
in a descending order. There was a minimum of two drug-free days between infusions.  
 
Locomotor Activity in an Open Field 




Following completion of dose-response relationships in the 5CSRTT, locomotor 
activity was quantified in an open field.  Locomotor activity was recorded in automated 
(43.2 X 43.2 cm) activity chambers (MED Associates, St. Albans, VT).  Each locomotor 
activity session consisted of a 30 min habituation period, after which the rat was 
removed from the chamber and administered a drug infusion.  Immediately following the 
infusion the rat was returned to the activity chamber for a 30 min test period.  Activity 
was assessed twice for each rat, once when VEH was infused and once when either 
BMI (25.0 ng/0.5 l/side) or MUS (50.0 ng/0.5 l/side) was infused.  The rats were 
tested according to their previous history (e.g., rats that had received BMI in the 
5CSRTT experiment were administered BMI during locomotor activity testing).  The 
order of vehicle versus drug administration was counterbalanced across rats.  Activity 
sessions were separated by at least 3-4 drug-free days.   
 
Intracranial Self-Stimulation 
Rats (n=12) used for the ICSS studies had not been used in the other tests.  The 
rats were trained on a continuous reinforcement schedule (FR1) to respond for brain 
stimulation (Carlezon and Chartoff, 2007; Paine et al., 2009).  Lever pressing resulted in 
the illumination of a 2-W house light and immediate delivery of a 0.5-s train of square-
wave cathodal pulses (0.1-ms pulse duration) at a set frequency of 141 Hz.  Responses 
during the 0.5-s stimulation period did not earn additional stimulation.  The stimulation 
current (200–350 A) was adjusted gradually to the lowest value that would sustain a 
reliable rate of responding (at least 40 rewards per minute).  




Once rats reliably lever pressed for stimulation, they were adapted to lever press 
for a descending series of stimulation frequencies.  Each series consisted of 15 1-min 
trials at each frequency.  Each trial consisted of a 5-s ―priming‖ phase during which non-
contingent stimulation was given, followed by a 50-s test phase during which the 
number of responses was counted and ended with a 5-s time-out period during which 
no stimulation was available.  The stimulation frequency was then lowered by ~10% 
(0.05 log10 units) and another trial was started.  After responding had been evaluated at 
each of the 15 frequencies, the procedure was repeated such that each rat was given 4 
series per day (60 min of training).  To characterize the functions relating response 
strength to reward magnitude, a least-squares line of best fit was plotted across the 
frequencies that sustained responding at 20, 30, 40, 50 and 60% of the maximum rate 
using customized analysis software.  The threshold for responding was defined as the 
frequency at which the line intersected the x-axis (theta-0).  Drug testing started when 
mean thresholds varied by less than 15% over three consecutive training sessions. 
Drug effects were quantified using the ―curve-shift‖ method of analysis (Carlezon 
and Chartoff, 2007; Paine et al., 2009).  This method can distinguish changes in 
motivation (as reflected by alterations in theta-0) from changes in response 
capabilities (as reflected by alterations in maximum response rates) (see 
Carlezon and Chartoff, 2007).  For each rat, three rate-frequency functions (―curves‖) 
were determined immediately prior to drug infusions.  The second and third curves were 
averaged to obtain the baseline (threshold and maximal response rate) parameters.  
Each rat was then infused with either BMI (0-25.0 ng/0.5 l/side) or MUS (0-50.0 ng/0.5 
l/side) and tested for an additional 15-min rate-frequency curve.  Rats were tested with 




both BMI and MUS; rats were given at least 7-10 drug-free days before testing on the 
alternate drug.  Doses of each drug were administered in either an ascending or 
descending fashion (counterbalanced across rats); tests with each drug dose were 
separated by at least two drug-free days.  
 
Histology 
Following the last test session rats were anesthetized with sodium pentobarbital 
(130 mg/kg, IP) and transcardially perfused with 0.9% NaCl followed by 4% 
paraformaldehyde.  A subset of animals was perfused 90 min following infusions of BMI, 
MUS, or VEH; the brains from these animals were used for Fos immunohistochemistry 
(see below).  Following perfusions, brains were removed, post-fixed for 24 h and then 
cryoprotected in 30% sucrose prior to slicing on a microtome.  Sections (40 m) were 
mounted on slides, stained with cresyl violet and placements assessed. 
 
Fos Immunohistochemistry 
Free-floating sections (40 m) from animals perfused 90 min following infusions 
were used to confirm changes in neuronal activity following manipulations of GABAA 
receptor activation.  Briefly, endogenous peroxidase activity was quenched by 
incubation in 0.3% H2O2 and then non-specific binding was blocked by a 2 h incubation 
in AB media (0.3% Triton X-100, 2% normal goat serum (Invitrogen, Carlsbad, CA) and 
1% bovine serum albumin (Sigma) in 0.01 M Tris buffered saline).  Sections were then 
incubated overnight with a polyclonal rabbit anti-c-Fos antibody (PC38T, Calbiochem, 
La Jolla, CA; 1:10,000 diluted in AB media).  The following day sections were washed, 




incubated for 1 h at room temperature in biotinylated goat anti-rabbit immunoglobulin G 
secondary antibody (Vector Laboratories, Burlingame, CA; 1:200 diluted in AB media) 
and then incubated with avidin-biotin-peroxidase complex (Vectastain ABC Elite kit; 
Vector Laboratories) for 30 min at room temperature.  Finally, sections were visualized 
using 0.05% 3,3‘-diaminobenzidine tetrahydrochloride containing 0.01% H2O2 (Vector 
Laboratories) for 10 min.  Rinsing in Tris buffered saline terminated the reaction. 
 
Statistical Analyses 
5CSRTT data and ICSS data were analyzed using separate one-way repeated 
measures ANOVAs with Dose as the within-subjects factor.  Locomotor activity data 
from habituation and test periods were analyzed separately using 2-way repeated 
measures ANOVAs with Condition (VEH, Drug [BMI or MUS]) and Time (10, 20, 30 min) 
as within-subjects factors.  Significant effects were further analyzed using 




Of the 29 rats tested, four animals were excluded (n = 1 for the BMI 
5CSRTT/locomotor activity; n = 1 for the MUS 5CSRTT/locomotor activity; and n = 2 for 
the ICSS experiment) from statistical analyses because their cannulae placements were 
outside the IL/PrL (Figure 1, Figure 2A-B).   
Fos immunohistochemistry was used to confirm that the BMI and MUS infusions 
had the expected effects on PFC neuronal activity.  Microinfusion of BMI (25 ng/0.5 




l/side) increased Fos-immunolabeling (Figure 2D), whereas MUS (50 ng/0.5 l/side) 
decreased Fos-immunolabeling (Figure 2F) relative to that observed when VEH was 
infused (Figure 2E).  These data confirm that BMI and MUS infusions altered neuronal 
activity at doses that were effective in the behavioral experiments.   
 
5-Choice Serial Reaction Time Task (5CSRTT) 
Intra-PFC administration of BMI (n = 7) affected accuracy (F[3, 18] = 3.20, P < 
.05, Figure 3), omissions (F[3, 18] = 30.67, P < .01), and reward retrieval latency (F[3, 
18] = 4.41, P < .05).  BMI (25.0 ng) decreased accuracy and increased the reward 
retrieval latency compared to VEH (all Ps < .05).  BMI (12.5-25.0 ng) increased 
omissions compared to VEH (all Ps < .05-.01).  All other measures were unaffected by 
BMI administration (all Fs[3, 18] < 2.48, n.s., Figure 3, Table I). 
Intra-PFC administration of MUS (n = 8) affected premature responses (F[4, 28] 
= 5.89, P < .05, Figure 4); MUS (50.0 ng) increased premature responses compared to 
VEH (P < .05).  All other measures were unaffected by MUS administration (all Fs[4, 28] 
< 1.07, n.s., Figure 4, Table I).   
 
Locomotor Activity 
Across the habituation period prior to BMI and VEH infusions, locomotor activity 
significantly decreased (F[2, 12] = 67.40, P < .01, Figure 5A); activity was higher during 
the first 10-min compared to the remainder of the habituation period (both Ps < .01).  
However, activity did not differ between the habituation period prior to VEH infusions as 
compared to that prior to BMI infusions (F[1, 6] < 1.0, n.s.), nor was there a significant 




Condition X Time interaction (F[2, 12] < 1.0, n.s.).  Activity significantly decreased 
across the test period (F[2, 12] = 9.67, P < .01); activity was higher during the first 10-
min compared to the remainder of the test period (both Ps < .01).  Activity was not 
different when VEH was infused as compared to when BMI was infused (F[1, 6] < 1.0, 
n.s.), nor was there a significant Condition X Time interaction (F[2, 12] < 1.0, n.s.). 
Across the habituation period prior to MUS and VEH infusions, locomotor activity 
significantly decreased (F[2, 14] = 123.34, P < .01, Figure 5B); activity was higher 
during the first 10-min compared to the remainder of the habituation period (both Ps < 
.01).  Activity did not differ between the habituation period prior to VEH infusions as 
compared to that prior to MUS infusions (F[1, 7] < 1.0, n.s.), nor was there a Condition X 
Time interaction (F[2, 14] < 1.0, n.s.).  Activity decreased across the test period (F[2, 14] 
= 29.87, P < .01); activity was higher during the first 10-min compared to the remainder 
of the test period (both Ps < .01).  During the test period activity was significantly higher 
when VEH infused as compared to when MUS was infused (F[1, 7] = 14.75, P < .01, 
Figure 5B Inset), but there was not a significant Condition X Time interaction (F[2, 14] 
= 3.19, n.s.).   
 
Intracranial self-stimulation 
A total of 10 rats were included in this portion of the experiment.  Intra-PFC 
infusions of BMI affected the threshold amount of stimulation required to maintain lever 
pressing (i.e., Theta 0) (F[3, 27] = 6.60, P < .01, Figure 6A-C), without affecting 
maximum rates of responding (F[3, 27] = 1.58, n.s.).  Intra-PFC infusions of 25 ng BMI 
significantly decreased the amount of stimulation required to maintain lever pressing 




compared to VEH infusions (BMI 0 ng; P < .01).  In contrast, intra-PFC infusions of MUS 
did not affect either ICSS thresholds or maximum rates of responding (Fs[4, 36] < 1.3, 
n.s., Figure 6D-F).    
 
Discussion 
Cortical GABAergic interneurons provide recurrent inhibition to pyramidal 
neurons, an effect that is postulated to stabilize cortical networks allowing for optimal 
cognitive performance (Winterer and Weinberger, 2004).  It has been proposed that 
disruptions in GABA transmission underlie cognitive deficits in schizophrenia (Lewis et 
al., 2005).  Here we show that blockade of cortical GABAA receptors with BMI caused a 
non-selective increase in cortical activity (as indicated by increased Fos 
immunolabeling) and impaired attention as measured by reduced accuracy of 
responding and increased omissions.   
Reductions in accuracy are the most reliable indicator of attentional 
deficits in the 5CSRTT (Robbins, 2002).  Although the accuracy impairment 
observed following intra-PFC BMI infusions was relatively small (~10%), it is of a 
similar magnitude as that observed in some PFC lesion experiments (Passetti et 
al., 2002; Passetti et al., 2003b) and following other manipulations (Passeti et al., 
2003a; Paine et al., 2007; Paine et al., 2009; Paine and Carlezon, 2009).  Moreover, 
the accuracy impairment was observed in combination with increased omissions, 
another potential indicator of attentional deficits.  Increased omissions in the 
5CSRTT can be attributed to various factors including (i) attentional deficits (rats 
fail to detect the stimulus presentation), (ii) motivational deficits (rats are 




unwilling to ‘work’ for the food pellet), or (iii) motor deficits (rats are unable to 
respond) (Robbins, 2002).  The pattern of results in the current experiment 
suggest that the increased omissions following intra-PFC BMI infusions reflect 
attentional deficits.  Although BMI infusions increased the latency to retrieve the 
sugar pellet reward, the effect was small (~300 ms) and rats exhibited normal 
food-seeking behavior (i.e., magazine entries).  Moreover, BMI decreased brain 
reward thresholds in the ICSS test, an effect that reflects enhanced motivation 
(Carlezon and Chartoff, 2007).  Thus it is unlikely that the increase in omissions 
results from decreased motivation to respond for a food reward.  Increased 
omissions may also indicate reductions in activity or motor capabilities.  Intra-
PFC BMI infusions did not, however, affect the latency to make a correct 
response, impulsive behavior (i.e., premature responding) or food-seeking 
behavior in the 5CSRTT.  Moreover, rats did not exhibit reductions in locomotor 
activity in the open field or in the capability to respond in the ICSS test.  These 
data suggest that intra-PFC BMI infusions did not cause gross motor deficits that 
interfered with the ability to nose-poke in the presence of the stimulus.  
Combined with the small but significant deficit in accuracy, the increase in 
omissions observed following intra-PFC BMI infusions most likely reflects an 
attentional deficit. 
Contrary to our hypothesis, stimulation of GABAA receptors with 
microinjections of MUS did not affect attention at any dose tested.  At the highest dose 
tested—which reduced PFC activity as indicated by decreased Fos immunolabeling—
PFC MUS infusions increased impulsive behavior as indicated by an increase in 




premature responding.  Increased impulsivity-like behavior cannot be easily explained 
by either increased locomotor activity (locomotor activity was decreased following MUS 
infusions) or increased reward sensitivity (which was unaffected by MUS infusions).  
Failure to find attentional improvements following low dose MUS infusions may not be 
surprising given that MUS is a full agonist at GABAA receptors, this likely results in non-
selective suppression of cortical activity, rather than the selective suppression which is 
likely necessary in order to synchronize specific cortical networks.  Future research 
investigating the role of positive allosteric modulators at GABAA receptors, which may 
be better suited to selectively potentiate GABAA receptor activation, is warranted.  
Moreover, the cognitive enhancing effects of positive allosteric modulators at GABAA 
receptors may be more robust in models exhibiting cognitive impairments.  Indeed, 
GABAA positive allosteric modulators enhance novel object recognition in rats that 
exhibited performance deficits following chronic phencyclidine treatment, a rodent 
model of schizophrenia (Damgaard et al., 2011).  
 One limitation of our within-subject design is that the rats received several 
infusions of the GABA drugs.  To mitigate any effects of repeated treatment on 
sensitivity to these drugs, we varied the order of treatment across subjects and 
ensured that there were drug-free days between tests.  The locomotor activity and 
ICSS experiments were intended to identify major effects on motor capabilities or 
motivation that could complicate interpretation of the attention tests.  It remains 
possible that more subtle changes in GABA receptor sensitivity could influence 
our results.  Our data provide a rationale for more detailed studies that are 
designed specifically to evaluate if intra-PFC treatment with BMI or MUS cause 




long-term changes in sensitivity to the behavioral effects of these drugs, and 
identify dose ranges of these drugs that are relevant for local microinfusions.  
Studies designed to evaluate experience-dependent alterations in drug sensitivity 
often involve repeated treatment and testing with a single dose (e.g., Todtenkopf 
and Carlezon, 2006) and thus are beyond the scope of the present work.  
 
Role of the PFC in attention  
The 5CSRTT quantifies sustained visuospatial attention and impulse 
control in rats and is analogous to the CPT used to quantify sustained attention 
in humans (Robbins, 2002).  We observed that over-activation and inactivation of a 
region encompassing both dorsal and ventral portions of the medial PFC resulted in 
dissociable deficits in the 5CSRTT.  We used alterations in the expression of Fos as 
an index of changes in the activity of these regions.  Although Fos is widely 
accepted as an indicator of neuronal activation, there are limitations of this 
approach: as one example, Fos induction can occur by activation of intracellular 
signaling pathways that do not necessarily lead to neuronal activation (Hoffman 
and Lyo, 2002).  This concern is mitigated in the present studies because the 
effects of MUS and BMI on cell activity are well characterized (Majchrzak et al., 
2000; Sawaguchi et al., 1989) and the direction of our effects corresponds with 
existing literature on the effects of these drugs.  Over-activation of the medial PFC 
impaired accuracy and increased omissions suggesting an attentional deficit, while 
inactivation of the medial PFC increased premature responding suggesting increased 
impulsive behavior.  This contrasts with previous observations following excitotoxic 




lesions: large lesions encompassing both dorsal and ventral subregions of the medial 
PFC lead to deficits in both cognitive domains, while those restricted to dorsal 
subregions (e.g., anterior cingulated cortex and/or PrL) induce attentional deficits and 
those restricted to ventral subregions (IL and/or orbitofrontal cortex) induce impulsive 
behavior (Chudasama et al., 2003; Passetti et al., 2002; Pezze et al., 2009; Muir et al., 
1996).  It is not entirely clear why temporary inactivation and excitotoxic lesions would 
result in disparate performance deficits in the 5CSRTT, but the discrepancy might be 
explained by compensatory changes that occur in projection areas following medial 
PFC lesions.  The PFC has top-down control over a number of subcortical structures 
with a putative role in cognitive behavior (e.g., nucleus accumbens (NAc) and 
hippocampus); long-term removal of this control may alter firing patterns in these 
structures.  For example, Pezze et al. (2009) suggested that both the attentional and 
impulse control deficits resulting from large medial PFC lesions are the result of 
increased D2 receptor activation in the NAc.  In contrast, temporary inactivation of the 
PFC decreases DA release, and hence receptor activation, in the NAc (Musare et al., 
1993).  Regardless, our Fos studies provide the basis for future studies in which 
electrophysiologic techniques are used to link changes in cellular activity with behavior. 
Although our data indicate that the medial PFC mediates attention, they also 
suggest that it is not necessary for optimal attention in well-trained animals.  When the 
medial PFC was temporarily taken ―off-line‖ by high doses of MUS, attention was not 
impaired.  In well-trained rats, subcortical structures may be sufficient to maintain 
attention via habit-like responding (Yin and Knowlton, 2006; Killcross and Coutureau, 
2003).  In contrast, attention was impaired when the PFC was non-specifically over 




activated by BMI infusions.  Not only would this over-activation disrupt neural synchrony 
within the PFC microcircuitry, but it would also disrupt synchrony within PFC target 
areas such as the NAc and hippocampus.  It has been proposed that optimal attentional 
performance results from specific activation of ‗task-relevant‘ pyramidal neurons and 
suppression of ―task-irrelevant‖ pyramidal neurons by GABA-mediated recurrent-
inhibition (Winterer and Weinberger, 2004); effectively this would result in activation of 
specific neurons in medial PFC target areas.  Thus over-activation and asynchrony in 
the PFC would effectively lead to disruptions in neural synchrony within target 
structures.  Currently, it is unclear if one specific projection area underlies the 
attentional deficits observed following PFC over-activation or whether these deficits 
result from disruptions across the entire neural network. 
The current experiments provide new insight on how manipulations that affect 
intracellular signaling processes may cause attentional deficits.  For example, disrupting 
the function of cyclic-AMP dependent protein kinase (PKA) or its downstream target 
CREB (cyclic AMP response element binding protein) within the PFC decreases 
accuracy and increases omissions in the 5CSRTT (Paine et al., 2009).  Decreasing 
either PKA or CREB function decreases neuronal excitability (Dong et al., 2006; Lopez 
et al., 2007; Trantham-Davidson et al., 2007), but the manipulations used are not cell-
type specific and may therefore decrease firing of either pyramidal neurons or GABA 
interneurons.  Given the similarity between the attentional deficits observed following 
disruption of the PKA signaling pathway and those following GABAA receptor 
antagonism, we speculate that disruption of either PKA or CREB function cause 
attentional deficits as a result of reduced GABA-mediated inhibition. 




Although the goal of the current experiment was to investigate the putative 
role in GABAA receptors in the attentional deficits observed in schizophrenia, 
attentional deficits are also involved in other psychiatric disorders (e.g., bipolar 
disorder, ADHD).  Dysregulation of neuronal firing could result from dysfunction 
in a variety of neurotransmitter systems (e.g., dopamine, acetylcholine).  Thus 
although other psychiatric disorders may have different pathologies, the net 
effect of these pathologies may result in cortical asynchrony and hence 
attentional deficits.  
 
Role of the PFC in Impulsive Behavior and Reward 
 The medial PFC, through its interactions with the NAc and ventral tegmental 
area, is postulated to regulate both impulsive behavior (Pattij et al., 2007; Pezze et al., 
2009; Pezze et al., 2007) and sensitivity to reward (Tzsckentke, 2000).  Moreover, 
impulsive action is hypothesized to be regulated, at least in part, by an increased 
motivation to obtain rewards (Fineberg et al., 2010).  In the current experiment we 
observed a dissociation between cortical manipulations that affected impulsive behavior 
and those that affected reward sensitivity.  Temporary inactivation of the medial PFC 
increased impulsive behavior without affecting sensitivity to reward, while over-action of 
the medial PFC increased sensitivity to reward without affecting impulsive behavior.  
Thus at least in the context of the 5CSRTT and ICSS, it appears that impulsivity and 
reward sensitivity can vary independently of one another.  
Increased premature responding following temporary inactivation of the medial 
PFC is consistent with the hypothesized role of this brain area in the regulation of 




impulsive behavior or the tendency toward rapid, unplanned actions (for review see 
Fineberg et al., 2010).  Moreover, our findings are consistent with the observed increase 
in premature responding in the 5CSRTT following excitotoxic lesions of ventral portions 
of the medial PFC (Chudasama et al., 2003; Passetti et al., 2002; Pezze et al., 2009) 
and with the observed increase in premature responding during a ―waiting task‖ 
following temporary inactivation of the PFC (Narayanan et al., 2006).  The effects of 
excitotoxic lesions on premature responding have been attributed to increased 
activation of D2 receptors in the NAc.  Indeed, D2 receptor antagonist infusions into the 
NAc normalize impulsive behavior (Pezze et al., 2009).  Temporary inactivation of the 
PFC however, would be expected to decrease, rather than increase, NAc DA (Musare 
et al., 1993, see below).  Thus the same mechanism cannot account for increased 
premature responding following temporary inactivation of the medial PFC.  Nonetheless, 
temporary inactivation and increased NAc DA following cortical excitotoxic lesions may 
ultimately have the same effect on NAc medium spiny neurons (MSNs)—namely a 
reduction in firing rate.  A reduction in excitatory drive to the NAc reduces MSN firing 
rate, as does increased D2 receptor activation (Carlezon and Thomas, 2009; Surmeier 
et al., 2007).  Thus reductions in MSN firing rate may underlie impulsive behavior that is 
observed following removal of the medial PFC.  
Over-activation of the medial PFC increased sensitivity to reward.  The regulation 
of reward by the medial PFC is thought to occur through a multisynaptic pathway 
involving the ventral tegmental area (VTA).  Indeed, intra-PFC BMI infusions enhance 
burst firing of putative VTA DA neurons (Enomoto et al., 2011).  Furthermore, electrical 
stimulation of the PFC increases DA release in the NAc, an effect that can be 




attenuated via blockade of glutamate receptors in the VTA (Taber et al., 1995).  
Similarly, application of glutamate to the PFC increases burst firing of VTA neurons and 
increases DA release in the NAc, while application of a local anesthetic to the PFC 
inhibits VTA neuron firing and reduces DA release in the NAc (Murase et al., 1993).   
 
Conclusions 
Acute blockade of cortical GABAA receptors increased PFC activity and caused 
attentional deficits in the 5CSRTT.  These findings add to a growing body of evidence 
supporting a role for GABA neuron dysfunction in the cognitive deficits observed in 
schizophrenia (see Lewis et al., 2005).  Attentional deficits are often observed in 
adolescents that are at-risk for developing schizophrenia before the onset of 
other signs of the disorder; following their onset, these deficits are stable across 
the course of illness (Cornblatt et al., 2001; Chen et al., 2000).  Our studies in 
adult rats provide the basis for future research that examines the 
neurodevelopmental role of GABA dysfunction in the etiology of attentional 
deficits observed in schizophrenia.  In addition, we show that the utility of full GABAA 
receptor agonists to treat such deficits is hampered the emergence unique cognitive 
deficits, raising the possibility that positive allosteric modulators at GABAA receptors 
might represent an alternative method by which alterations in GABA receptor function 
could be utilized to reverse cognitive deficits in this schizophrenia.    
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Table I.  Effects of BMI and MUS on 5CSRTT Performance 
 Magazine Entries 
 
Correct Latency (sec) 
BMI   
0.0 103.7 9.3 0.81  0.6 
6.25 129.9  22.7 0.75  0.06 
12.5 163.9  28.2 0.97  0.04 
25.0 116.4  19.9 0.94  0.15 
MUS   
0.0 107.9  15.8 0.84  0.04 
6.25 107.3  17.0 0.77  0.04 
12.5 95.0  13.3 0.80  0.04 
25.0 96.1  12.3 0.80  0.07 
50.0 100.4  16.4 0.80  0.06 
Note: Neither magazine entries or the correct response latency were affected by intra-
PFC infusions of bicuculline (BMI) or muscimol (MUS). 
 





Fig 1. Schematic drawing showing the location of injector tips in the medial PFC of rats 
infused with bicuculline (left, n=7) or muscimol (right, n=8) and tested in the 5-
choice serial reaction time task.  Rats were excluded (not shown) if their tips 
were not within the boundary of either the prelimbic (PrL) or infralimbic (IL) 
cortex.  Numbers on the left indicate location forward from bregma.  Adapted 
from Paxinos and Watson (1997). 
 
Fig 2. Effects of manipulating cortical GABAA receptor activation on c-Fos expression. 
A) Schematic of the PFC approximating location of cannulae placements 
(Paxinos and Watson, 1997). Box indicates field of view in Panel B.  B) 
Representative cannula placements indicating guide cannulae and obturator; 
injectors were the same length as the obturator.  C) Schematic of the PFC 
approximating the field of view in Panels D-F (Paxinos and Watson, 1997).  Intra-
PFC infusions of the GABAA receptor antagonist bicuculline (BMI; 25.0 ng/0.5 
l/side) increased c-Fos expression (D), while intra-PFC infusions of the GABAA 
receptor agonist muscimol (MUS; 50.0 ng/0.5 l/side) decreased c-Fos 
expression (F) relative to vehicle (VEH) infusions (E).  All infusions were 
administered 90 min before the rats were killed. PrL, Prelimbic cortex; IL, 
infralimbic cortex. 
 
Fig 3. Effects of intra-PFC infusions of the GABAA receptor antagonist bicuculline on 
performance in the 5-choice serial reaction time task.  Intra-PFC infusions of 




bicuculline (n=7) decreased accuracy (P < .05) (A) and increased both omissions 
(P < .01) (B) and the reward retrieval latency (P < .05) (D).  Bicuculline infusions 
did not affect premature responses (C).  **P < .01, *P < .05 from 0.0 (Bonferroni 
Multiple Comparison test). 
 
Fig 4. Effects of intra-PFC infusions of the GABAA receptor agonist muscimol on 
performance in the 5-choice serial reaction time task.  Intra-PFC infusions of 
muscimol (n=8) increased premature responses (P < .05) (C), but did not affect 
accuracy (A), omissions (B) or the reward retrieval latency (D).  *P < .05 from 0.0 
(Bonferroni Multiple Comparison test). 
 
Fig 5. Effects of modulating cortical GABAA receptor activation on locomotor activity.  
Rats were habituated to the chambers for 30 min, infused with bicuculline (BMI; 
25.0 ng/0.5l/side; n=7), muscimol (MUS; 50.0 ng/0.5l/side; n=8) or their 
respective vehicles (VEH) and tested for an additional 30 min.  Inset shows total 
activity during the habituation and test sessions.  BMI did not affect locomotor 
activity (A). During the test, MUS decreased the total locomotor activity (P < .01) 
(B), but there was not a significant time X condition interaction.  **P < .01 from 
VEH (main effect of Condition). 
 
Fig 6. Effects of modulating cortical GABAA receptor activation on intra-cranial self-
stimulation thresholds.  Representative rate-frequency curves from rats (n=10) 
that received intra-PFC infusions of either A) bicuculline (BMI; 25.0 ng/0.5l/side) 




or D) muscimol (MUS; 50.0 ng/0.5l/side) in comparison to when they were 
treated with vehicle (VEH).  BMI (25.0 ng/0.5l/side) decreased the threshold for 
responding (P < .01) (B) without affecting maximum rates of responding (C).  
MUS did not affect either the threshold of responding (E) or the maximum rate of 
responding (F).  **P < .01 from 0.0 (Bonferroni Multiple Comparison test). 
 
 
 
 
